Search

The Chelonaplysilla genus possesses a numerous bioactive diterpenes with anti-inflammatory and cytotoxic effects. The current study aimed to assess the chemical composition of C. erecta crude extract (CECE) based on its metabolomic profile that has been integrated with neural network-based virtual screening and molecular docking using liquid chromatography with high resolution mass spectrometry (LCHR-MS). In addition to the estimation of the antitumor activity of the same extract via anti-interleukin-17A (IL-17) action, along with its formulated spanlastics preparation. The CECE markedly displayed growth inhibition for HepG-2 cells at IC50 value 16.5 ± 0.8 μg/mL, whereas the spanlastic formulation revealed more eminent antitumor effect against Caco-2 cells (IC50 = 2.8 ± 0.03 μg/mL). Among the dereplicated compounds, macfarlandin F (16) and pourewanone (25) demonstrated the highest potential with co-crystallized ligand 63 O within the active site of IL-17A in molecular docking studies. These findings rationalized the antitumor mechanism of marine organism for future chemotherapeutic applications. [ABSTRACT FROM AUTHOR]

Background: Atorvastatin reduces blood cholesterol levels, although there is evidence linking statins in general to memory loss. Objective: To evaluation of atorvastatin effects against memory and cognition in normal and hyperlipidemic male albino rats. Materials and Methods: 24 male adult albino rats, have been used and in random way divided into four groups with six rats in each group as follows; 1) Control group: normal diet group, 2) HFD group: orally HFD-fed group in a dose of (15 gram/animal/day) for 28 days, 3) Atorvastatin/ordinary diet group: treated with atorvastatin orally (10 mg/kg/day) for 14 days; from 29th day to 42nd day of the study, 4) Atorvastatin/HFD group: treated with atorvastatin orally (10 mg/kg/day) for 14 days; from the 29th day to the 42nd day of the study. Assessment of working memory and spatial learning was performed after the 42nd day of the experiment. Results: Treatments with atorvastatin were significantly ameliorated this lipid dysfunction as it significantly reduced cholesterol, LDL-C and VLDL levels, increased HDL-C levels but did not affect triglycerides. Atorvastatin exhibited beneficial effects against hyperlipidemia induced by HFD treatment. Administration of atorvastatin in atorvastatin/ordinary diet-fed group also induced a statistically significant increase in AchE level in comparison with control group, while administration of atorvastatin attenuated AchE in Atorvastatin/HFD group compared with non-treated HFD group. Conclusion: Administration of atorvastatin in atorvastatin/ordinary diet-fed group also induced an oxidative status as indicated by disturbance of oxidative stress markers (GSH, and CAT), while administration of atorvastatin in Atorvastatin/HFD group improved both oxidative stress markers (GSH, and CAT) as well as inflammatory markers (TNF-a and IL-1ß) compared with non-treated HFD group. [ABSTRACT FROM AUTHOR]